| After AGTC Deal Flops, Biogen Bets $800M on Gene Therapy Rival Nightstar | Ben Fidler | 03/04/19 | Boston |
| Roche Bets $4.8B on Spark Therapeutics and the Future of Gene Therapy | Ben Fidler | 02/25/19 | National |
| Passage Bio Gets $116M As Wilson, Yamada Team Up On Gene Therapy Again | Ben Fidler | 02/14/19 | National |
| Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More | Frank Vinluan | 02/01/19 | National |
| With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy | Ben Fidler | 01/31/19 | New York |
| 15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) | Ben Fidler | 12/18/18 | National |
| Bio Roundup: ASH Wrap, CRISPR Baby Fallout, Moderna’s Record IPO | Ben Fidler | 12/07/18 | National |
| Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel | Ben Fidler | 11/09/18 | National |
| Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More | Frank Vinluan | 10/26/18 | National |
| With $90M Round, Stoke Eyes a “Spinraza For Epilepsy” And a 2019 IPO | Ben Fidler | 10/23/18 | Boston |
| Novartis Buys Endocyte for $2.1B, Making a Second Bet on Radiotherapy | Frank Vinluan | 10/18/18 | Indiana |
| Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More | Alex Lash | 10/12/18 | National |
| Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More | Frank Vinluan | 10/05/18 | National |
| LogicBio Jumps on the Gene Therapy 2.0 Wave and Lines Up an IPO | Frank Vinluan | 09/26/18 | Boston |
| Bio Roundup: CRISPR Tests, Parkinson’s Questions, Opioid Bills & More | Frank Vinluan | 04/27/18 | National |
| SMA Day: AveXis Gene Therapy Creeps Forward as Biogen Drug’s Sales Slow | Ben Fidler | 04/25/18 | Boston |
| Biogen Pays $1B to Broaden Ionis Pact, Betting More on RNA Drugs | Ben Fidler | 04/20/18 | Boston |
| Bio Roundup: Lung Cancer Showdown, Gene Therapy Deals, IPO Busts | Ben Fidler | 04/13/18 | National |
| Novartis Bets $8.7B on AveXis’s Gene Therapy for Spine Disease | Ben Fidler | 04/09/18 | National |
| After Paper Shakes Sector, Gene Therapy Leader Jim Wilson Talks Safety | Ben Fidler | 01/30/18 | National |
| Solid Discloses Duchenne Problems in IPO & Raises Rival’s Hackles | Ben Fidler | 01/25/18 | Boston |
| Disney, Family Offices Back Second Bio Startup from Tech Entrepreneur Haney | Corie Lok | 01/23/18 | Boston |
| Spark CEO Marrazzo on Gene Therapy Pricing & Paving the Way for the Field | Ben Fidler | 01/12/18 | National |
| Notes From the JPM ’18 Vortex: Gene Therapy’s Reckoning and Lonely Cabs | Ben Fidler | 01/11/18 | National |
| 15 For ’18: Key Clinical Data to Watch For Next Year (Part 1) | Ben Fidler | 12/04/17 | National |
| Alnylam Data Puts a Nobel Discovery One Step Closer to Approved Drug | Ben Fidler | 09/20/17 | Boston |
| Bio Roundup: GOP Drama, Immunotherapy Setbacks, Pharma Revamps | Ben Fidler | 07/28/17 | National |
| Biogen, Opening Bottlenecks, Sees Spine Drug Sales, Shares Rise | Ben Fidler | 07/25/17 | Boston |
| Bio Roundup: Trumpcare Is Mean, SCOTUS Says Go, Merck’s Myeloma No | Ben Fidler | 06/16/17 | National |
| Will New Data Open “Bottlenecks” For Biogen’s Pricey Spine Drug? | Ben Fidler | 04/26/17 | Boston |
